GlassScriptPhysician profile
Aaron D Edwards
NPI 1457902702
$4,309.08
in general payments reported to CMS, 2019-2025
30 companies · $913 in 2025
The $913 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $971 · 2022: $938 · 2023: $563 · 2024: $925 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,039 · Education: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,039.02 |
| Education | $360.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,140.55 | 2021-2025 | Xtandi, Myrbetriq, Veozah |
| Endo Pharmaceuticals INC. | $355.90 | 2021-2024 | Xiaflex, Aveed |
| Abbvie INC. | $349.76 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $344.05 | 2023-2025 | Gemtesa, Orgovyx |
| Antares Pharma, INC. | $331.42 | 2021-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $226.44 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $194.27 | 2021-2023 | Prolaris |
| Urovant Sciences INC | $162.28 | 2021-2022 | |
| Janssen Biotech, INC. | $121.68 | 2021-2022 | |
| Allergan, INC. | $120.87 | 2021-2022 | |
| Endo USA, INC. | $92.86 | 2024-2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $83.29 | 2024-2025 | |
| Axonics, INC. | $68.38 | 2021-2024 | Bulkamid |
| Accord Healthcare, INC. | $67.44 | 2022-2024 | |
| Medtronic, INC. | $66.84 | 2021-2025 | Interstim |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $64.23 | 2021-2024 | Speedicath |
| Progenics Pharmaceuticals, INC. | $63.00 | 2022-2023 | Pylarify |
| Hollister Incorporated | $61.32 | 2022-2023 | Infyna Chic |
| Dendreon Pharmaceuticals LLC | $59.12 | 2025 | Provenge |
| 180 Medical, INC. | $46.75 | 2023-2025 | Cure Catheter |
| Acerus Pharmaceuticals Corporation | $43.95 | 2021-2022 | |
| Blue Earth Diagnostics | $42.95 | 2021-2022 | |
| Teleflex LLC | $40.65 | 2021-2024 | Urolift |
| Tolmar, INC. | $31.89 | 2023-2024 | |
| Pfizer INC. | $31.16 | 2021-2022 | |
| Olympus America INC. | $28.22 | 2025 | Itind System |
| Ethicon US, LLC | $20.78 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.01 | 2024 | Lynparza |
| Kerecis Limited | $16.31 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boston Scientific Corporation | $15.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.